Inclusion Criteria:  Patients with severe COPD (FEV ≤ 50% of theoretical values) hospitalized for exacerbation; COPD treated for at least one year with one (or more successive) combination of at least two inhaled drugs: either a Long-Acting Beta2-Adrenergic bronchodilator (LABA) combined with a corticosteroid (CSI), or a LABA combined with a long-acting anti-cholinergic bronchodilator (LAMA), or a triple combination LABA/LAMA/CSI; History of at least one severe COPD exacerbation (treated with antibiotics and/or oral corticosteroids) in the two years preceding the study; Ex-smokers (at least 6 months of withdrawal) or active daily smokers of more than 10 pack-years; Severe dyspnea in basal state before hospitalization (mMRC stage ≥ 2); Age between 40 and 85 years old; Perfect understanding of the French language; Have signed a consent form; Be affiliated to a health insurance plan.  Exclusion Criteria:  Re-hospitalization for severe exacerbation in the 6 months preceding the study; Chronic inflammatory disease (rheumatic, etc...) treated with systemic corticosteroid therapy; Long-term oxygen therapy (exclusive ambulatory oxygen therapy is not a non-inclusion criterion); Unstable cardiovascular pathology (right or left heart failure, coronary artery disease); Cancer under treatment or follow-up; Pregnant women; Deprived of liberty or under guardianship.